February 5, 2007 – Wyeth will collaborate with MediVas of San Diego and Nautilus of France to develop new drugs for hemophilia; Wyeth also signed a deal worth up to $110 million with elbion NV to develop a therapy for schizophrenia and psychosis; AstraZeneca paid $120 million to license antibody technology from Regneron; Arena completed enrollment in a 3,000 patient Phase III trial for its obesity drug; SciClone will speed up its development work on an infectious disease compound; ImClone and Bristol-Myers Squibb asked for approval in Japan of Erbitux for advanced colorectal cancer; and Columbia Labs took a 68% hit after announcing that Progesterone failed a Phase III trial as a drug to prevent preterm births. The Centient Biotech 200™ fell 12 points to 4055, a loss of .29%. More details...
